The session runs from 2 – 4:45 p.m. EST Thursday, Nov. 5, and features the traditional presidential address, keynote lecture, and recognition of the ACR Gold Medal Award and ARP Lifetime Achievement Award recipients in addition to the Year in Review.

JAK inhibitors have taken on a greater role in rheumatology, and this year’s Great Debate will feature two experts discussing whether they should be used before biologics if methotrexate fails.

Advances in single-cell sequencing have the potential to provide unique insights into the etiology of rheumatic diseases and facilitate the development of new therapies, according to Alex Kuo, PhD.

Recent and ongoing studies continue to lead researchers toward new pathways and new targets for novel therapies to relieve disability and distress in patients with OA and RA.

Two pediatric rheumatologists will review childhood the systemic lupus erythematosus complications thrombotic microangiopathies and macrophage activation syndrome.

Considered by many the heart and pulse of any ACR annual meeting, the poster sessions for ACR Convergence 2020 will continue in a virtual format that will bring many improvements for both poster presenters and viewers.